- Details
- Description
-
Packaging Size60t/bottle
-
Strength40mg
-
CompositonAsciminib
-
TreatmentChronic myeloid leukemia，CML
-
FormTablet
-
BrandLuciAsc
-
Quantity Unit40mg*60t/box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Asciminib
Asciminib is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Asciminib is a protein kinase inhibitor.
Chronic Myeloid Leukemia
Newly diagnosed
- Indicated in adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)
- 80 mg PO daily OR 40 mg PO BID
- Continue for as long as clinical benefit is observed or until unacceptable toxicity
Previously treated
- Indicated in adults with previously treated Ph+ CML in CP
- 80 mg PO daily OR 40 mg PO BID
- Continue for as long as clinical benefit is observed or until unacceptable toxicity
With T315I mutation
- Indicated in adults with Ph+ CML in CP with T315I mutation
- 200 mg PO BID
- Continue for as long as clinical benefit is observed or until unacceptable toxicity
